Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 5/20 | 0.41 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.41 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.41 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13042083 | 0.79 | SRD5A2 (0.43) | PPARDPPARASLC16A3SLC16A1MCTS1 | |
| SCHEMBL8935846 | 0.78 | PPARA (0.50) | PPARDPPARASRD5A2MAOBPPARG | |
| SCHEMBL24208446 | 0.76 | HDAC1 (0.53) | HDAC1HDAC7LDHBSRD5A2P2RY14 | |
| SCHEMBL2966998 | 0.70 | PTGDR2 (0.36) | PPARASRD5A2P2RY14MAOBPTGDR2 | |
| SCHEMBL2982666 | 0.69 | SRD5A2 (0.42) | SRD5A2TGM2 | |
| SCHEMBL2971499 | 0.69 | GCGR (0.38) | HDAC1HDAC7PPARDPPARASLC16A3 | |
| SCHEMBL3440032 | 0.65 | L3MBTL1 (0.53) | HDAC1HDAC7LDHBMAOBTGM2 | |
| SCHEMBL3440003 | 0.65 | LDHB (0.57) | HDAC1HDAC7LDHB | |
| SCHEMBL8935661 | 0.65 | SLC16A3 (0.46) | PPARASLC16A3SLC16A1MCTS1MAOB | |
| SCHEMBL2820265 | 0.65 | PPARA (0.53) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | HDAC1 147/4885HDAC7 952/4885PPARD 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.